Delving into the Latest Updates on Zhejiang Ruijiamei Biotechnology Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Neoplasms

Single-chain FV antibody fragment

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Single-chain FV antibody fragment	1

Top 5 Target	Count

BCMA(B-cell maturation protein)	1

主要研究目的评价在难治性SLE受试者中输注RJMty19注射液的安全性和耐受性；确定RJMty19注射液治疗难治性系统性红斑狼疮受试者的MTD和/或RP2D。次要研究目的：评价在SLE受试者中输注RJMty19注射液后的初步疗效；评价在SLE受试者中输注RJMty19注射液后的PK特征。探索性目的：探索同种异体CD19-CAR-DNT细胞在体内的增殖和持续性与疗效之间的相关性；探索免疫细胞数与疗效之间的相关性；探索PD指标与疗效之间的相关性。

[Translation]

Main study objectives To evaluate the safety and tolerability of RJMty19 injection infusion in refractory SLE subjects; To determine the MTD and/or RP2D of RJMty19 injection in the treatment of refractory SLE subjects. Secondary study objectives: To evaluate the preliminary efficacy of RJMty19 injection infusion in SLE subjects; To evaluate the PK characteristics of RJMty19 injection infusion in SLE subjects. Exploratory objectives: To explore the correlation between the proliferation and persistence of allogeneic CD19-CAR-DNT cells in vivo and the efficacy; To explore the correlation between the number of immune cells and the efficacy; To explore the correlation between PD indicators and the efficacy.

Start Date16 May 2024

Sponsor / Collaborator

Zhejiang Ruijiamei Biotechnology Co., Ltd.

NCT05453669

/ RecruitingPhase 1IIT

Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

To evaluate the safety and tolerability of CD19-CAR-DNT cells infusion in subjects with relapsed/refractory B-cell non-Hodgkin's Lymphoma

Start Date15 Jun 2022

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+1]

100 Clinical Results associated with Zhejiang Ruijiamei Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Ruijiamei Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Ruijiamei Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Ruijiamei Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Login to view more data